About ERLEADA®
ERLEADA® is an androgen receptor (AR) inhibitor indicated to treat mCSPC and nmCRPC1
mCSPC = metastatic castration-sensitive prostate cancer; nmCRPC = non-metastatic castration-resistant prostate cancer.
Reference
1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.